The Dangers of Statin Treatments - Interviews Dr. Malcolm Kendrick

A 2015 systematic review of statin trials found that in primary prevention trials, the median postponement of death was just 3.2 days. In secondary prevention trials, death was postponed 4.1 days.
A 2018 review presents substantial evidence that total cholesterol and LDL cholesterol levels are not an indication of heart disease risk, and that statin treatment is of “doubtful benefit” as a form of primary prevention for this reason.
Tactics used in statin studies to exaggerate benefits include excluding unsuccessful trials, cherry-picking data, ignoring the most important outcome — an increase in life expectancy — and using a statistical tool called relative risk reduction to amplify trivial effects.
If you look at absolute risk, statin drugs benefit just 1% of the treated participants. Out of 100 people treated with statins for five years, one person will have one less heart attack.
Statin trials minimize health risks by using a run-in period. Participants are given the drug for a few weeks, after which those who suffer adverse effects are simply excluded, thereby lowering the perceived frequency and severity of side effects.

Subscribe for FREE to the latest health news: https://bit.ly/3nuOvoP

Website: https://bit.ly/3zhdkau

Podcast: https://bit.ly/3zeWk4x

Facebook: https://www.facebook.com/doctor.health/
Instagram: https://www.instagram.com/drmercola
Twitter: https://twitter.com/mercola
Telegram: https://t.me/DoctorMercola
Truth: https://truthsocial.com/@Mercola
Gab: https://gab.com/Mercola
Gettr: https://gettr.com/user/mercola
Mewe: https://mewe.com/p-front/dr.josephmercola